Vertex Pharmaceuticals (VRTX) to Release Earnings on Monday

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) is projected to issue its Q4 2024 quarterly earnings data after the market closes on Monday, February 10th. Analysts expect the company to announce earnings of $3.99 per share and revenue of $2.78 billion for the quarter. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS.Parties that are interested in registering for the company's conference call can do so using this link.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing analysts' consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. On average, analysts expect Vertex Pharmaceuticals to post $-2 EPS for the current fiscal year and $16 EPS for the next fiscal year.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX traded down $14.75 during midday trading on Tuesday, reaching $455.22. 1,560,864 shares of the stock traded hands, compared to its average volume of 1,594,048. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20. The stock has a market capitalization of $117.23 billion, a PE ratio of -228.75, a P/E/G ratio of 1.80 and a beta of 0.41. Vertex Pharmaceuticals has a one year low of $377.85 and a one year high of $519.88. The company's 50 day moving average is $435.95 and its 200 day moving average is $462.13.

Wall Street Analyst Weigh In

A number of research firms have recently commented on VRTX. Morgan Stanley increased their target price on Vertex Pharmaceuticals from $450.00 to $459.00 and gave the company an "equal weight" rating in a research report on Tuesday. Wells Fargo & Company cut Vertex Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $460.00 price objective for the company. in a report on Thursday, January 30th. Royal Bank of Canada upped their price objective on Vertex Pharmaceuticals from $402.00 to $407.00 and gave the company a "sector perform" rating in a research report on Tuesday. JPMorgan Chase & Co. cut their price objective on Vertex Pharmaceuticals from $503.00 to $500.00 and set an "overweight" rating on the stock in a research report on Monday, December 23rd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $550.00 price objective on shares of Vertex Pharmaceuticals in a research report on Tuesday. Ten research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $505.29.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.